LILRB2 (IO-108 Biosimilar) Recombinant Monoclonal Antibody
-
貨號:CSB-RA839793MB4HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:LILRB2 (IO-108 Biosimilar Antibody)重組單克隆抗體是一種專為科研用途開發(fā)的生物試劑,旨在滿足生命科學領(lǐng)域?qū)γ庖哒{(diào)控分子研究的需求。該抗體以白細胞免疫球蛋白樣受體B2(LILRB2)為靶向目標,通過重組DNA技術(shù)在工程細胞中表達并純化獲得,具有高特異性和批次穩(wěn)定性,為相關(guān)機制研究提供可靠工具。 LILRB2作為免疫球蛋白超家族成員,在免疫細胞(如巨噬細胞、樹突狀細胞)表面廣泛表達,通過識別MHC I類分子及其他配體參與免疫抑制信號傳導,與腫瘤免疫逃逸、自身免疫疾病等病理過程密切相關(guān)。本產(chǎn)品通過精準結(jié)合LILRB2胞外結(jié)構(gòu)域,可用于探究其在免疫調(diào)節(jié)中的分子機制,包括信號通路激活、細胞功能調(diào)控及疾病模型中的作用。 該重組抗體采用人源化或小鼠單克隆抗體框架設(shè)計,經(jīng)蛋白A/G親和層析及離子交換層析純化,純度達95%以上,內(nèi)毒素水平低于0.1 EU/μg,確保實驗結(jié)果的準確性與可重復性。適用于多種科研應用,如及細胞功能實驗等,助力研究人員在基礎(chǔ)免疫學、腫瘤免疫學及神經(jīng)免疫學等領(lǐng)域開展深入探索。 本產(chǎn)品僅用于實驗室研究,不可用于診斷或治療用途。使用時需嚴格遵循標準實驗操作規(guī)范,建議根據(jù)具體應用場景優(yōu)化抗體稀釋比例及反應條件。通過提供高質(zhì)量的LILRB2靶向工具,為揭示免疫調(diào)控網(wǎng)絡(luò)、開發(fā)新型治療策略提供重要實驗支持。
-
Uniprot No.:
-
基因名:
-
別名:IO108 research-grade biosimilar; IO 108 research-grade biosimilar; IO-108 research-grade biosimilar ;LILRB2 antibody; ILT4 antibody; LIR2 antibody; MIR10 antibody; Leukocyte immunoglobulin-like receptor subfamily B member 2 antibody; LIR-2 antibody; Leukocyte immunoglobulin-like receptor 2 antibody; CD85 antigen-like family member D antibody; Immunoglobulin-like transcript 4 antibody; ILT-4 antibody; Monocyte/macrophage immunoglobulin-like receptor 10 antibody; MIR-10 antibody; CD antigen CD85d antibody
-
反應種屬:Human
-
免疫原:Recombinant Human LILRB2 protein
-
免疫原種屬:Homo sapiens (Human)
-
標記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應用說明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:3-4 weeks
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點詳情
-
功能:Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Involved in the down-regulation of the immune response and the development of tolerance. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M) triggering differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance. Competes with CD8A for binding to class I MHC antigens. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
-
亞細胞定位:Cell membrane; Single-pass type I membrane protein.
-
組織特異性:Expressed in monocytes and at lower levels in myeloid and plasmacytoid dendritic cells. Expressed in tolerogenic IL10-producing dendritic cells. Expressed in myeloid-derived suppressor cells during pregnancy. Detected at low levels in natural killer (NK)
-
數(shù)據(jù)庫鏈接:
Most popular with customers
-
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-















